Shockwave C2+ Debut Joins Packed Shockwave Agenda at Transcatheter Cardiovascular Therapeutics Conference in San Francisco
SANTA CLARA, Calif., Oct. 20, 2023 (GLOBE NEWSWIRE) -- Shockwave Medical, Inc. (NASDAQ: SWAV), a pioneer in the development and commercialization of transformational technologies for the treatment of cardiovascular disease, announced today the planned U.S. introduction of the Shockwave C2+ Coronary Intravascular Lithotripsy (IVL) catheter following approval by the U.S. Food and Drug Administration. The Shockwave C2+ catheter provides 50 percent more pulses per catheter than the Shockwave C2 catheter that was approved in the U.S. in 2021. The enhanced C2+ catheter will make its U.S. debut at the 35th Transcatheter Cardiovascular Therapeutics (TCT) annual scientific symposium of the Cardiovascular Research Foundation, with the full commercial launch planned for the beginning of November. Sanitary Flange Fittings
“The enhancements of Shockwave C2+ will be an added benefit of IVL for optimally treating complex calcium, including more diffuse disease, as well as nodular and thick, eccentric calcium,” said Richard Shlofmitz, MD, Chairman, Department of Cardiology, St. Francis Hospital in Roslyn, New York, who performed the first U.S. commercial case with Shockwave C2+. “When additional pulses are added to the existing intuitive catheter design and simple-to-use system that are foundational to the success of Shockwave IVL, the result is an updated catheter that can enhance workflow and improve procedural efficiency.”
TCT23 to Feature New Coronary IVL Data and Insights and Symposia on COSIRA-II
The following scientific sessions and symposia supporting Shockwave Medical’s growing portfolio of technologies and clinical studies will be taking place at TCT:
TCT WorldLink Latin America Featured Clinical Science: Complex Coronary Intervention
Shock India Registry: Multicenter Registry of Coronary IVL in Calcified Coronary Arteries in Real-World Indian Patient Population
10:30 AM – 10:41 AM; Presentation Theater 3, Room 215, Level 2, Moscone South
Prof. Ashok Seth, MBBS*, Fortis Escorts Heart Institute & Research Centre
The COSIRA-II Trial: Designed To Demonstrate Refractory Angina Relief with the Coronary Sinus Reducer
2:00 PM – 3:00 PM, Presentation Theater 1, Room 205, Level 2, Moscone South
Gregg W. Stone, MD, Mount Sinai Heart Health System; Allen Jeremias, MD*, St. Francis Hospital; Timothy D. Henry, MD, The Christ Hospital; Prof. Stefan Verheye*, ZNA Middelheim Hospital; Megha Prasad, MD, New York-Presbyterian Columbia University Irving Medical Center
TOPSHOCK: Vote for this Year’s Best Coronary IVL Case
11:00 AM – 12:00 PM, Presentation Theater 1, Room 205, Level 2, Moscone South
Prof. James C. Spratt, MD*, St. George's University Hospitals NHS Trust; Ziad Ali, MD*, St. Francis Hospital; Kalaivani Mahadevan, MD*, Portsmouth Hospitals University NHS Trust; Tim O’Connor, MD*, Beaumont Hospital; Sameh Sayfo, MD*, Baylor Scott & White, The Heart Hospital
Coronary Spotlight Session: Calcium – How Hard Should We Try?
Coronary IVL in the US: Trends, Hospital Variation, & Predictors of Use: Insights From the ACC NCDR CathPCI Registry
10:42 AM – 10:50 AM, Coronary Spotlight Theater, Hall E, Exhibition Level, Moscone North
Neel Butala, MD*, UCHealth University of Colorado Hospital
Coronary IVL: More Pulses, More Data, More Insights
12:45 PM – 1:45 PM, Presentation Theater 2, Room 208, Level 2, Moscone South
Yousif Ahmad, M.D.*, Yale Medicine; Neel Butala, MD*, UCHealth University of Colorado Hospital; Prof. Ashok Seth, MBBS*, Fortis Escorts Heart Institute & Research Centre; Prof. Gennaro Sardella, MD*, Presso Policlinico Umberto; Ziad Ali, MD*, St. Francis Hospital; Darshan Doshi, MD*, Massachusetts General Hospital
A detailed agenda for all Shockwave Medical symposia and featured presentations can be found here.
Shockwave C2+ is commercially available for the treatment of de novo coronary artery disease in the United States, Europe and select other geographies.
About Shockwave Medical, Inc.
Shockwave Medical is a leader in the development and commercialization of innovative products that are transforming the treatment of cardiovascular disease. Its first-of-its-kind Intravascular Lithotripsy (IVL) technology has transformed the treatment of atherosclerotic cardiovascular disease by safely using sonic pressure waves to disrupt challenging calcified plaque, resulting in significantly improved patient outcomes. Shockwave has also recently acquired the Neovasc Reducer, which is under clinical investigation in the United States and Canada, and is CE Marked in the Europe. By redistributing blood flow within the heart, the Reducer is designed to provide relief to the millions of patients worldwide suffering from refractory angina. Learn more at www.shockwavemedical.com and www.neovasc.com.
About Reducer While under clinical investigation in the COSIRA-II trial (U.S. and Canada), the Reducer is CE-marked for the treatment of refractory angina, a painful and debilitating condition that occurs when the coronary arteries deliver an inadequate supply of blood to the heart muscle, despite treatment with standard revascularization or cardiac drug therapies. It affects millions of patients worldwide, who typically lead severely restricted lives as a result of their disabling symptoms, and its incidence is growing. The Reducer provides relief of angina symptoms by altering blood flow within the myocardium of the heart and increasing the perfusion of oxygenated blood to ischemic areas of the heart muscle. Placement of the Reducer is performed using a minimally invasive transvenous procedure.
Stainless Steel 304l Flanges This press release contains statements relating to our expectations, projections, beliefs, and prospects, which are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. In some cases, you can identify these statements by forward-looking words such as “may,” “might,” “will,” “should,” “expects,” “plans,” “anticipates,” “believes,” “estimates,” “predicts,” “potential” or “continue,” and similar expressions, and the negative of these terms. Forward-looking statements in this press release include, but are not limited to, statements r